The following post was published on the Knowledge@Wharton website on January 22, 2014. The data is in, and there is no question that 2013 was the most active year for biotechnology initial public ...

The founder of a successful public biotechnology company once told me that the secret to his company's success was neither the idea nor the concept, but the management team: from day one the ...

Enthusiasm for using biotech to meet societal energy challenges is at levels not seen since the early 1980s 1,2,3,4,5, when understanding and capability in the life sciences were at a radically ...

Last year was a record 12 months for venture-backed biotech and pharma companies, with deal activity rising to $28.5 billion from $17.8 billion in 2019. As vaccines roll out, drug development ...

Five more venture-backed biotechnology companies were set to begin public trading Thursday, after each priced within or above its expected range. All five companies priced within or above their ...

Mayor Bill de Blasio’s plan to award nearly $40 million in grants for biotech developments further bolsters an industry that had a record-setting 2020. De Blasio’s latest funding pledge for ...

Shares of Shift4 Payments Inc and Legend Biotech Corp soared in their U.S. market debuts on Friday, capping the best week for initial public offerings in two years.

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate ...

Oxford Sciences Innovation has contributed to a banner week for University of Oxford spinouts. The £320 million ($462 million) fund, which lists Google Ventures and Neil Woodford among its ...

Basel, July 15, 2014 - Novartis announced today a collaboration with Banner Alzheimer's Institute (BAI) on a pioneering clinical study in Alzheimer's disease (AD) prevention.